133 related articles for article (PubMed ID: 2910481)
1. Effect of novobiocin on the antitumor activity and tumor cell and bone marrow survivals of three alkylating agents.
Eder JP; Teicher BA; Holden SA; Cathcart KN; Schnipper LE; Frei E
Cancer Res; 1989 Feb; 49(3):595-8. PubMed ID: 2910481
[TBL] [Abstract][Full Text] [Related]
2. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
Teicher BA; Herman TS; Tanaka J; Eder JP; Holden SA; Bubley G; Coleman CN; Frei E
Cancer Res; 1991 Feb; 51(4):1086-91. PubMed ID: 1825474
[TBL] [Abstract][Full Text] [Related]
3. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
Teicher BA; Herman TS; Holden SA; Epelbaum R; Liu SD; Frei E
Cancer Res; 1991 Feb; 51(3):780-4. PubMed ID: 1988117
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of pentoxifylline as a modulator of alkylating agent activity in vitro and in vivo.
Teicher BA; Holden SA; Herman TS; Epelbaum R; Pardee AB; Dezube B
Anticancer Res; 1991; 11(4):1555-60. PubMed ID: 1746913
[TBL] [Abstract][Full Text] [Related]
5. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo.
Teicher BA; Holden SA; Eder JP; Brann TW; Jones SM; Frei E
Cancer Res; 1989 Nov; 49(21):5994-8. PubMed ID: 2790813
[TBL] [Abstract][Full Text] [Related]
6. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma.
Teicher BA; Holden SA; al-Achi A; Herman TS
Cancer Res; 1990 Jun; 50(11):3339-44. PubMed ID: 2334928
[TBL] [Abstract][Full Text] [Related]
7. Preclinical studies and clinical correlation of the effect of alkylating dose.
Frei E; Teicher BA; Holden SA; Cathcart KN; Wang YY
Cancer Res; 1988 Nov; 48(22):6417-23. PubMed ID: 3180059
[TBL] [Abstract][Full Text] [Related]
8. Combination of etanidazole with cyclophosphamide and platinum complexes.
Teicher BA; Herman TS; Shulman L; Bubley G; Coleman CN; Frei E
Cancer Chemother Pharmacol; 1991; 28(3):153-8. PubMed ID: 1830248
[TBL] [Abstract][Full Text] [Related]
9. A phase I clinical trial of novobiocin, a modulator of alkylating agent cytotoxicity.
Eder JP; Wheeler CA; Teicher BA; Schnipper LE
Cancer Res; 1991 Jan; 51(2):510-3. PubMed ID: 1985770
[TBL] [Abstract][Full Text] [Related]
10. Combination chemotherapy with a new folate analog: activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models.
Schmid FA; Sirotnak FM; Otter GM; DeGraw JI
Cancer Treat Rep; 1987; 71(7-8):727-32. PubMed ID: 3607784
[TBL] [Abstract][Full Text] [Related]
11. Etoposide with lonidamine or pentoxifylline as modulators of alkylating agent activity in vivo.
Tanaka J; Teicher BA; Herman TS; Holden SA; Dezube B; Frei E
Int J Cancer; 1991 Jun; 48(4):631-7. PubMed ID: 2045206
[TBL] [Abstract][Full Text] [Related]
12. Response of drug-sensitive and -resistant L1210 leukemias to high-dose chemotherapy.
Griswold DP; Trader MW; Frei E; Peters WP; Wolpert MK; Laster WR
Cancer Res; 1987 May; 47(9):2323-7. PubMed ID: 3567926
[TBL] [Abstract][Full Text] [Related]
13. Combination of N,N',N"-triethylenethiophosphoramide and cyclophosphamide in vitro and in vivo.
Teicher BA; Holden SA; Cucchi CA; Cathcart KN; Korbut TT; Flatow JL; Frei E
Cancer Res; 1988 Jan; 48(1):94-100. PubMed ID: 3121169
[TBL] [Abstract][Full Text] [Related]
14. Schedule-dependent variations in the response of murine P388 leukemia to cyclophosphamide in combination with interferons-alpha/beta.
Borden EC; Sidky YA; Hatcher JF; Bryan GT
Cancer Res; 1988 May; 48(9):2329-34. PubMed ID: 3356000
[TBL] [Abstract][Full Text] [Related]
15. Effect of fluosol-DA/carbogen on etoposide/alkylating agent antitumor activity.
Teicher BA; Bernal SD; Holden SA; Cathcart KN
Cancer Chemother Pharmacol; 1988; 21(4):281-5. PubMed ID: 3131032
[TBL] [Abstract][Full Text] [Related]
16. Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines.
Teicher BA; Cucchi CA; Lee JB; Flatow JL; Rosowsky A; Frei E
Cancer Res; 1986 Sep; 46(9):4379-83. PubMed ID: 3731096
[TBL] [Abstract][Full Text] [Related]
17. Acute in vivo resistance in high-dose therapy.
Teicher BA; Ara G; Keyes SR; Herbst RS; Frei E
Clin Cancer Res; 1998 Feb; 4(2):483-91. PubMed ID: 9516940
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma.
Holden SA; Teicher BA; Ara G; Herman TS; Coleman CN
J Natl Cancer Inst; 1992 Feb; 84(3):187-93. PubMed ID: 1542129
[TBL] [Abstract][Full Text] [Related]
19. Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine.
Schwartz GN; Teicher BA; Eder JP; Korbut T; Holden SA; Ara G; Herman TS
Cancer Chemother Pharmacol; 1993; 32(6):455-62. PubMed ID: 8258194
[TBL] [Abstract][Full Text] [Related]
20. Effect of a bovine hemoglobin preparation on the response of the FSaIIC fibrosarcoma to chemotherapeutic alkylating agents.
Teicher BA; Herman TS; Hopkins RE; Menon K
J Cancer Res Clin Oncol; 1992; 118(2):123-8. PubMed ID: 1735732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
